News and Announcements
Xerion is pleased to announce the launch of their Pre-IPO funding round
- Published August 12, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Xerion is undertaking a Pre-IPO raising of $2.7M at $0.40 cents per share with an attaching 1:2 option at an exercise price of $0.50. These funds are to support a key asset purchase, targeted R&D, working capital, pursue US prescription market expansion opportunities and IPO costs. An IPO is planned for late November 2021 providing Pre-IPO investors a viable exit strategy.
An investment in Xerion gives investors exposure to established large global market opportunities in acne, fungal nail disease, atopic dermatitis, psoriasis and rosacea. These markets are estimated to be worth in excess of US$37B globally.
Xerion is an Australian based specialty pharmaceutical company focusing on key dermatological indications using its proprietary active ingredient, AMYCOT®. Xerion has a CONSUMER HEALTH division focusing on Over the Counter (OTC) sales in Australia and select international markets as well as a PRESCRIPTION division aimed at the lucrative USA market.
Xerion’s first product, nailKALM® is designed for the treatment of Onychomycosis (fungal nail disease) and is sold as an OTC product in Australia. The product is clinically proven and TGA listed to treat fungal nail disease. Chemist Warehouse is our largest Australian customer and have recently launched an exciting national TV campaign that showcases the unique benefits of nailKALM® – Chemist Warehouse nailKALM TVC – June 2021 . nailKALM® is also sold directly to podiatrists.
About Xerion Limited
Xerion is an Australian based specialty pharmaceutical company whose focus is to build a US prescription drug pipeline of 5 new products using AMYCOT® for key dermatological indications.
AMYCOT® is a powerful natural ingredient derived from a strain of spirulina (Arthrospira maxima). AMYCOT® has been shown to have excellent anti-inflammatory, anti-bacterial, anti-fungal and skin regenerative properties through extensive pre-clinical and clinical evidence. This proprietary technology is naturally derived, has no reported significant side effects and is cost effective to produce.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
